ByonGuard™: Best-in-Class Masking Platform

Many tumor-associated antigens (TAAs) targeted by antibody therapies are also present in health tissue, causing on-target off-tumor toxicity, affecting treatment safety and limiting combination options. This fundamental challenge forces clinicians and patients to choose between efficacy and safety.  

Our innovative ByonGuard™ platform, a best-in-class steric masking technology providing a universal solution to reduce off-tumor toxicity, aims to eliminate this trade-off. Unlike traditional masking approaches that demand custom peptide design for each target, ByonGuard™ offers a universal masking solution that can be applied broadly across multiple targets and antibody scaffolds, accelerating development timelines and expanding partnering flexibility.